Last updated on November 2019

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)


Brief description of study

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

Clinical Study Identifier: NCT03518086

Find a site near you

Start Over
Sorry. There are no research sites conducting this study in the radius provided. ( View all Sites )
If you would like to be informed of other studies that may be of interest to you, you may sign up for CenterWatch.com's Patient Notification Service. ( Sign Up )